Heart Rate in Coronary Artery Disease: Should We Lower It?
详细信息 查看全文
- 作者：Kelly Axsom MD (1)
Sripal Bangalore MD ; MHA ; FACC ; FSCAI (1) - 关键词：Coronary artery disease ; Heart rate ; Prognosis ; Reduction
- 刊名：Current Treatment Options in Cardiovascular Medicine
- 出版年：2013
- 出版时间：February 2013
- 年：2013
- 卷：15
- 期：1
- 页码：118-128
- 全文大小：265KB
- 参考文献：1. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol. 1997;30:1104鈥?. CrossRef
2. Coburn AF, Grey RM, Rivera SM. Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A-J mouse. Johns Hopkins Med J. 1971;128(4):169鈥?3.
3. Anderson GF, Chu E. Expanding priorities鈥攃onfronting chronic disease in countries with low income. N Engl J Med. 2007;356(3):209鈥?1. CrossRef
4. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349(9061):1269鈥?6. CrossRef
5. Reunanen A, et al. Heart rate and mortality. J Intern Med. 2000;247(2):231鈥?. CrossRef
6. Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J. 1997;18(9):1404鈥?0. CrossRef
7. Benetos A, et al. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension. 1999;33(1):44鈥?2. CrossRef
8. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1991;121:172鈥?. CrossRef
9. Kannel WB, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113(6):1489鈥?4. CrossRef
10. Jouven X, et al. Predicting sudden death in the population: the Paris Prospective Study I. Circulation. 1999;99(15):1978鈥?3. CrossRef
11. Gillman MW, et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993;125(4):1148鈥?4. CrossRef
12. Palatini P, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002;162(20):2313鈥?1. CrossRef
13. Paul L, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2010;55(2):567鈥?4. CrossRef
14. Disegni E, et al. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. J Clin Epidemiol. 1995;48(10):1197鈥?05. CrossRef
15. Zuanetti G, et al. Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction: insights from the GISSI-2 study. Eur Heart J. 1998;19 Suppl F:F19鈥?6.
16. Bangalore S, et al. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J. 2010;31(5):552鈥?0. Evaluation of nearly 140,000 patients with non-ST-segment elevation myocardial infarction found a J-shaped curve relationship between resting heart rate and all-cause mortality. Lowest mortality rates were seen with heart rates between 60鈥?9聽bpm, heart rates鈥?lt;鈥?0聽bpm and鈥夆墺鈥?00聽bpm were associated with increased mortality rates. CrossRef
17. Eagle KA, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727鈥?3. CrossRef
18. Morrow DA, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031鈥?. CrossRef
19. Kushner FG, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205鈥?1. CrossRef
20. Anderson JL, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1鈥揺157. CrossRef
21. Diaz A, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26(10):967鈥?4. CrossRef
22. Fox K, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817鈥?1. CrossRef
23. Steg PG, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One. 2012;7(5):e36284. CrossRef
24. Kolloch R, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29(10):1327鈥?4. CrossRef
25. Bangalore S, et al. Heart rate in patients with coronary artery disease - the lower the better? An analysis from the Treating to New Targets (TNT) trial (Abstr). Eur Heart J. 2011;32:339.
26. Bangalore S, et al. Relationship of Heart Rate and Cardiovascular Events in Patients after Acute Coronary Syndromes: An Analysis from the PROVE-IT TIMI 22 Trial. J Am Coll Cardiol. 2010;55:A98, E924.
27. Cucherat M, Borer JS. Reduction of resting heart rate with antianginal drugs: review and meta-analysis. Am J Ther. 2012;19(4):269鈥?0. CrossRef
28. Palatini P, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens. 2006;24(4):603鈥?0. CrossRef
29. Dahlof B, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895鈥?06. CrossRef
30. Poulter NR, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366(9489):907鈥?3. CrossRef
31. Poulter NR, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009;54(13):1154鈥?1. CrossRef
32. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52(18):1482鈥?. CrossRef
33. Williams B, Lacy PS. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol. 2009;54(8):705鈥?3. For the same effect on reduction of brachial systolic pressure, atenolol was shown to have a higher central systolic pressure compared to amlodipine due to the reduction in heart rate. CrossRef
34. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57(12):43F鈥?F. CrossRef
35. Hjalmarson A. Significance of reduction in heart rate in cardiovascular disease. Clin Cardiol. 1998;21(12 Suppl 2):II3鈥?.
36. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2(8498):57鈥?6.
37. Roberts R, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83(2):422鈥?7. CrossRef
38. Chen ZM, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622鈥?2. CrossRef
39. Jneid, H., et al. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline and Replacing the 2011 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2012. 2012 ACC/AHA Update of the unstable angina and non-ST segement elevation myocardial infarction guidelines.
40. Kushner FG, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271鈥?06. 2009 ACC/AHA Update ST-segement elevation myocardial infarction guidelines. CrossRef
41. Bangalore S, et al. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J. 2008;156(2):241鈥?. CrossRef
42. Gullestad L, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 2005;45(2):252鈥?. CrossRef
43. Lechat P, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103(10):1428鈥?3. CrossRef
44. Poldermans D, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341(24):1789鈥?4. CrossRef
45. Bangalore S, et al. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet. 2008;372(9654):1962鈥?6. CrossRef
46. Kramer JM, et al. National evaluation of adherence to beta-blocker therapy for 1聽year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152(3):454 e1鈥?. CrossRef
47. Smith Jr SC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363鈥?2. CrossRef
48. Gibbons RJ, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina鈥攕ummary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41(1):159鈥?8. CrossRef
49. Fox K, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807鈥?6. CrossRef
50. Borer JS, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817鈥?3. CrossRef
51. Tardif JC, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529鈥?6. CrossRef
52. Bohm M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376(9744):886鈥?4. SHIFT trial results, confirming that elevated heart rate in patients with chronic systolic heart failure is associated with worse outcomes. Ivabradine reduced heart rate and decreased primary end-point of cardiovascular death or hospitalization for heart failure. CrossRef
53. Sa Cunha R, et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens. 1997;15(12 Pt 1):1423鈥?0. CrossRef
54. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol. 1998;18(5):677鈥?5. CrossRef
55. Huikuri HV, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1999;19(8):1979鈥?5. CrossRef
56. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104(13):1477鈥?2. CrossRef
57. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153(8):1589鈥?01. CrossRef
58. Sambuceti G, et al. Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation. 1997;95(12):2652鈥?. CrossRef
59. Tanaka N, et al. Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol. 1990;40(4):503鈥?1. CrossRef
60. Sugimachi M, et al. Reduction of myocardial oxygen demand by controlling heart rate and hemodynamics simultaneously by novel circulatory model. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:4297鈥?00.
61. Guth BD, et al. Mechanisms of benefit in the ischemic myocardium due to heart rate reduction. Basic Res Cardiol. 1990;85 Suppl 1:157鈥?6.
62. Guth BD, et al. Role of heart rate reduction in the treatment of exercise-induced myocardial ischaemia. Eur Heart J. 1987;8(Suppl L):61鈥?. CrossRef
63. Pratt CM, et al. Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study). Am J Cardiol. 1996;77(15):1302鈥?. CrossRef
64. Nagatsu M, et al. Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. Circulation. 2000;101(6):653鈥?. CrossRef
65. Thackray SD, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J. 2006;152(4):713 e9鈥?3. CrossRef
66. Bolli R, Fisher DJ, Entman ML. Factors that determine the occurrence of arrhythmias during acute myocardial ischemia. Am Heart J. 1986;111(2):261鈥?0. CrossRef
67. Reynolds RD, Calzadilla SV, Lee RJ. Spontaneous heart rate, propranolol, and ischaemia-induced ventricular fibrillation in the dog. Cardiovasc Res. 1978;12(11):653鈥?. CrossRef
68. Bauer A, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet. 2006;367(9523):1674鈥?1. CrossRef
69. Ghuran A, et al. Heart rate turbulence-based predictors of fatal and nonfatal cardiac arrest (The Autonomic Tone and Reflexes After Myocardial Infarction substudy). Am J Cardiol. 2002;89(2):184鈥?0. CrossRef
70. Camm AJ, et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation. 2004;109(8):990鈥?. CrossRef
71. La Rovere MT, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation. 2001;103(16):2072鈥?. CrossRef
72. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984;226(4671):180鈥?. CrossRef
73. Beere PA, Glagov S, Zarins CK. Experimental atherosclerosis at the carotid bifurcation of the cynomolgus monkey. Localization, compensatory enlargement, and the sparing effect of lowered heart rate. Arterioscler Thromb. 1992;12(11):1245鈥?3. CrossRef
74. Kaplan JR, et al. Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation. 1987;76(6):1364鈥?2. CrossRef
75. Effects of ivabradine in patients with stable coronary artery disease without heart failure. 2012 website]. Available from: http://www.controlled-trials.com/ISRCTN61576291. Accessed October 1, 2012. - 作者单位：Kelly Axsom MD (1)
Sripal Bangalore MD, MHA, FACC, FSCAI (1)
1. The Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY, 10016, USA
文摘